Home » FDA Adds Dexamethasone to COVID-19 Temporary Compounding Lists
FDA Adds Dexamethasone to COVID-19 Temporary Compounding Lists
Drugs Regulatory Affairs
The FDA has added dexamethasone to the list of drugs that may be compounded under its temporary policy allowing compounders to produce the drug during the COVID-19 pandemic.
Demand for the anti-inflammatory drug surged in mid-June after UK researchers reported that it reduced deaths in critically ill COVID-19 patients.
Five suppliers of dexamethasone are currently on the FDA’s drug shortages list — AuroMedics Pharma, Fresenius Kabi USA, Hikma Pharmaceuticals USA, Mylan Institutional and Somerset Therapeutics.